FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2164492854> ?p ?o ?g. }

• W2164492854 abstract "This study tested the hypothesis that Major Histocompatibility Complex (MHC) incompatible equine mesenchymal stromal cells (MSCs) would induce cytotoxic antibodies to donor MHC antigens in recipient horses after intradermal injection. No studies to date have explored recipient antibody responses to allogeneic donor MSC transplantation in the horse. This information is critical because the horse is a valuable species for assessing the safety and efficacy of MSC treatment prior to human clinical application. Six MHC heterozygote horses were identified as non-ELA-A2 haplotype by microsatellite typing and used as allogeneic MHC-mismatched MSC recipients. MHC homozygote horses of known ELA-A2 haplotype were used as MSC and peripheral blood leukocyte (PBL) donors. One MHC homozygote horse of the ELA-A2 haplotype was the recipient of ELA-A2 donor MSCs as an MHC-matched control. Donor MSCs, which were previously isolated and immunophenotyped, were thawed and culture expanded to achieve between 30x106 and 50x106 cells for intradermal injection into the recipient’s neck. Recipient serum was collected and tested for the presence of anti-donor antibodies prior to MSC injection and every 7 days after MSC injection for the duration of the 8-week study using the standard two-stage lymphocyte microcytotoxicity dye-exclusion test. In addition to anti-ELA-A2 antibodies, recipient serum was examined for the presence of cross-reactive antibodies including anti-ELA-A3 and anti-RBC antibodies. All MHC-mismatched recipient horses produced anti-ELA-A2 antibodies following injection of ELA-A2 MSCs and developed a wheal at the injection site that persisted for the duration of the experiment. Anti-ELA-A2 antibody responses were varied both in terms of strength and timing. Four recipient horses had high-titered anti-ELA-A2 antibody responses resulting in greater than 80% donor PBL death in the microcytotoxicity assays and one of these horses also developed antibodies that cross-reacted when tested on lymphocyte targets from a horse with an unrelated MHC type. Allogeneic MSCs are capable of eliciting antibody responses in vivo that can be strong and also cross-reactive with MHC types other than that of the donor. Such responses could limit the effectiveness of repeated allogeneic MSC use in a single horse, and could also result in untoward inflammatory responses in recipients." @default.
• W2164492854 created "2016-06-24" @default.
• W2164492854 creator A5011662443 @default.
• W2164492854 creator A5012216419 @default.
• W2164492854 creator A5022616846 @default.
• W2164492854 creator A5039924479 @default.
• W2164492854 creator A5048819993 @default.
• W2164492854 creator A5059515326 @default.
• W2164492854 creator A5085022285 @default.
• W2164492854 date "2015-04-12" @default.
• W2164492854 modified "2023-10-17" @default.
• W2164492854 title "Equine allogeneic bone marrow-derived mesenchymal stromal cells elicit antibody responses in vivo" @default.
• W2164492854 cites W1522803969 @default.
• W2164492854 cites W1560273623 @default.
• W2164492854 cites W16821395 @default.
• W2164492854 cites W1689389897 @default.
• W2164492854 cites W1790809173 @default.
• W2164492854 cites W1917952603 @default.
• W2164492854 cites W1947261266 @default.
• W2164492854 cites W1970484465 @default.
• W2164492854 cites W1998461585 @default.
• W2164492854 cites W1998941039 @default.
• W2164492854 cites W2006955905 @default.
• W2164492854 cites W2009960651 @default.
• W2164492854 cites W2013123708 @default.
• W2164492854 cites W2014565491 @default.
• W2164492854 cites W2015162024 @default.
• W2164492854 cites W2026598157 @default.
• W2164492854 cites W2033597878 @default.
• W2164492854 cites W2042487476 @default.
• W2164492854 cites W2044285352 @default.
• W2164492854 cites W2044695442 @default.
• W2164492854 cites W2045075275 @default.
• W2164492854 cites W2046216444 @default.
• W2164492854 cites W2046873552 @default.
• W2164492854 cites W2047003816 @default.
• W2164492854 cites W2050470070 @default.
• W2164492854 cites W2050600834 @default.
• W2164492854 cites W2054248603 @default.
• W2164492854 cites W2061981400 @default.
• W2164492854 cites W2074432289 @default.
• W2164492854 cites W2078457908 @default.
• W2164492854 cites W2082873908 @default.
• W2164492854 cites W2092504238 @default.
• W2164492854 cites W2095643785 @default.
• W2164492854 cites W2109452029 @default.
• W2164492854 cites W2115426954 @default.
• W2164492854 cites W2119774673 @default.
• W2164492854 cites W2138374638 @default.
• W2164492854 cites W2142648420 @default.
• W2164492854 cites W2143463625 @default.
• W2164492854 cites W2150604071 @default.
• W2164492854 cites W2156100905 @default.
• W2164492854 cites W2159037149 @default.
• W2164492854 cites W2159358845 @default.
• W2164492854 cites W2159999899 @default.
• W2164492854 doi "https://doi.org/10.1186/s13287-015-0053-x" @default.
• W2164492854 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4414005" @default.
• W2164492854 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25889095" @default.
• W2164492854 hasPublicationYear "2015" @default.
• W2164492854 type Work @default.
• W2164492854 sameAs 2164492854 @default.
• W2164492854 citedByCount "95" @default.
• W2164492854 countsByYear W21644928542015 @default.
• W2164492854 countsByYear W21644928542016 @default.
• W2164492854 countsByYear W21644928542017 @default.
• W2164492854 countsByYear W21644928542018 @default.
• W2164492854 countsByYear W21644928542019 @default.
• W2164492854 countsByYear W21644928542020 @default.
• W2164492854 countsByYear W21644928542021 @default.
• W2164492854 countsByYear W21644928542022 @default.
• W2164492854 countsByYear W21644928542023 @default.
• W2164492854 crossrefType "journal-article" @default.
• W2164492854 hasAuthorship W2164492854A5011662443 @default.
• W2164492854 hasAuthorship W2164492854A5012216419 @default.
• W2164492854 hasAuthorship W2164492854A5022616846 @default.
• W2164492854 hasAuthorship W2164492854A5039924479 @default.
• W2164492854 hasAuthorship W2164492854A5048819993 @default.
• W2164492854 hasAuthorship W2164492854A5059515326 @default.
• W2164492854 hasAuthorship W2164492854A5085022285 @default.
• W2164492854 hasBestOaLocation W21644928541 @default.
• W2164492854 hasConcept C126322002 @default.
• W2164492854 hasConcept C142724271 @default.
• W2164492854 hasConcept C147483822 @default.
• W2164492854 hasConcept C151730666 @default.
• W2164492854 hasConcept C159654299 @default.
• W2164492854 hasConcept C198826908 @default.
• W2164492854 hasConcept C203014093 @default.
• W2164492854 hasConcept C207936829 @default.
• W2164492854 hasConcept C2780007613 @default.
• W2164492854 hasConcept C2780762169 @default.
• W2164492854 hasConcept C2911091166 @default.
• W2164492854 hasConcept C71924100 @default.
• W2164492854 hasConcept C86803240 @default.
• W2164492854 hasConceptScore W2164492854C126322002 @default.
• W2164492854 hasConceptScore W2164492854C142724271 @default.
• W2164492854 hasConceptScore W2164492854C147483822 @default.
• W2164492854 hasConceptScore W2164492854C151730666 @default.
• W2164492854 hasConceptScore W2164492854C159654299 @default.
• W2164492854 hasConceptScore W2164492854C198826908 @default.

• next